A National Decision Point: Effective Testing and Screening for Covid-19


This Duke-Margolis report out provides a framework for public health officials and community leaders in schools, businesses and other institutions on how to use Covid-19 screening test strategies to operate safely and prevent further spread of the virus. A National Decision Point: Effective Testing and Screening for Covid-19, was developed with funding from the Rockefeller Foundation, and aims to be a useful tool to help officials customize screening strategies of asymptomatic people to local circumstances and risk – with a particular focus on higher-risk populations and suppressing community spread.






McClellan, Mark, Christina Silcox, David Anderson, Anna Zavodszky, Ethan Borre, Susan Dentzer and Mara Aspinall (2020). A National Decision Point: Effective Testing and Screening for Covid-19. Retrieved from https://hdl.handle.net/10161/21539.



Mark B McClellan

Professor of the Practice of Business Administration

Mark McClellan, MD, PhD, is a physician-economist who focuses on quality and value in health care, including payment and coverage reform, real-world evidence, more effective policies to support drug and device innovation, and initiatives to increase the impact of health care, public health, and social service programs on population health. His work on responding to the COVID-19 public health emergency spanned virus containment and testing strategies, reforming health care toward more resilient models of delivering care, and accelerating the development of therapeutics and vaccines, including a COVID-19 response roadmap. He is former commissioner of the U.S. Food and Drug Administration, and former administrator of the Centers for Medicare & Medicaid Services, where he developed and implemented major reforms in health policy. He has also served as a member of the President’s Council of Economic Advisors and as a Deputy Assistant Secretary for Economic Policy at the Department of the Treasury. He was previously Associate Professor of Economics with tenure at Stanford University.  Dr. McClellan is an independent board member on the boards of Johnson & Johnson, Cigna, Alignment Healthcare, and PrognomIQ; chairs the National Academy of Medicine’s Leadership Consortium for a Value and Science-Driven Health System; co-chairs the Guiding Committee for the Health Care Payment Learning and Action Network; and serves as an advisor for Blackstone Life Sciences, Arsenal Capital Partners, and MITRE.


Christina Silcox

Adjunct Assistant Professor in the Duke-Margolis Center for Health Policy

Material is made available in this collection at the direction of authors according to their understanding of their rights in that material. You may download and use these materials in any manner not prohibited by copyright or other applicable law.